← All trials
NCT06788938
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 21, 2025
- Primary completion
- Apr 24, 2028
- Completion date
- Apr 24, 2029
- First posted
- Jan 23, 2025
- Last posted
- May 22, 2025
- Enrollment
- 29
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, Los AngelesLead sponsor
- University of California, Los AngelesOfficial
- AmgenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.